Is Anthropic’s IPO a Good Reason to Buy Ginkgo Bioworks Right Now?
The AI developer's offering will give it a pile of cash that it might choose to spend on biomedical research automation.
Ginkgo Bioworks, a lab-automation biotech company, is poised to potentially collaborate with Anthropic, an AI company planning to go public. Ginkgo's cart-based system is designed to be modular, expandable, robust, and customizable, which could be beneficial for Anthropic as it shifts its focus towards bioscience. While Ginkgo's third-quarter 2026 revenue fell 6% year-over-year to $28 million and reported a $41 million net loss, its unique approach to developing an autonomous lab has shown potential.
A pilot program with OpenAI resulted in a 40% reduction in the production cost of a test protein. Ginkgo's cloud lab services are also being utilized by frontier AI labs. However, Ginkgo's stock performance and potential collaboration with Anthropic remain uncertain at this point.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.